The fresh infusion of capital will enable ImmunoACT to fast-track the scale-up of its lead candidate HCAR-19 by expansion of the multi-location cGMP facilities and R&D of new product pipeline. “This investment will further help ImmunoACT to gear up for the manufacture of more treatments,” said Satyanarayana Chava, founder and CEO of Laurus Labs.
